1-2 of 2
Natalia Glushko
Close
Sort by
Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 896.
https://doi.org/10.1182/blood.V130.Suppl_1.896.896
Published: 2017
Journal Articles

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Michael J. Mauro, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Roberto Uehara, Eric Leip, PhD, Liza DeAnnuntis, Nathalie Bardy-Bouxin, PhD, Andreas Hochhaus, MD, Timothy H. Brümmendorf, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1620.
https://doi.org/10.1182/blood.V130.Suppl_1.1620.1620
Published: 2017